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INTRODUCTION
Postoperative nausea and vomiting (PONV) is a common and 
unpleasant experience for surgical patients undergoing general 
anesthesia.1,2 The incidence of PONV is approximately 20–30%, 
although it can be as high as 80% in patients with risk factors.1 
PONV may result in adverse events such as prolongation of the 
recovery period, delay of discharge, and postsurgical complica-
tions, and as such, it should be prevented by adequate man-
agement.3,4
Selective 5-hydroxytryptamine type 3 (5-HT3) receptor an-
tagonists have been widely researched and are currently used 
as the primary therapy for PONV prevention, as they have few-
er side-effects such as sedation or extrapyramidal symptoms 
than other antiemetics.5-7 Although 5-HT3 receptor antago-
nists have significantly reduced PONV, it is reported that over 
35% of patients treated with ondansetron experience PONV.3 
One reason for this unsatisfactory response may be individual 
differences in the biotransformation and disposition of 5-HT3 
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receptor antagonists due to gene polymorphisms related to 
pharmacokinetics.1,3 However, the variations in gene coding 
for the 5-HT3 receptor as a target structure of the drug may 
also affect the extent of PONV and the antiemetic effects of 
5-HT3 receptor antagonists.8-11
In previous pharmacogenomic studies, Y129S and -100_ 
-102AAG deletion variants of the 5-HT3B receptor gene were 
found to be possibly associated with nausea induced by parox-
etine and the clinical response of 5-HT3 receptor antagonists 
for chemotherapy-induced nausea and vomiting (CINV), re-
spectively.9,10,12,13 We thus hypothesized that these polymor-
phisms might have a relationship with the therapeutic failure of 
5-HT3 receptor antagonists for PONV treatment. In this study, 
we investigated whether the Y129S and -100_-102AAG dele-
tion polymorphisms as variants of the 5-HT3B receptor gene 
affect the efficacy of ondansetron in preventing PONV in pa-
tients undergoing general anesthesia for laparoscopic surgery.
MATERIALS AND METHODS
After obtaining Institutional Review Board approval and writ-
ten informed consent from all patients, 288 adult patients of 
the American Society of Anesthesiologists (ASA) physical sta-
tus I or II and ages 18 to 65 years who were scheduled to un-
dergo laparoscopic cholecystectomy were recruited in this 
study. Before the surgery, all patients were interviewed to de-
termine their past medical history, including tobacco and al-
cohol use, the presence of previous postoperative nausea or 
vomiting, and motion sickness. Patients with a history of drug 
abuse, a known prolongation of the QTc interval on electrocar-
diography, morbid obesity (body mass index >31 kg/m2), anti-
emetics use within 24 hours before the study, and significant 
hepatic or renal disease were excluded from the study.
Patients did not receive premedication. Upon arrival in the 
operating room, all patients were monitored with electrocardi-
ography, noninvasive blood pressure, and pulse oximetry. An-
esthesia was induced with thiopental 4–5 mg/kg, remifentanil 
1.0 μg/kg, and rocuronium 0.6 mg/kg. After induction of anes-
thesia, the patients’ lungs were ventilated with 50% oxygen. 
Anesthesia was maintained with sevoflurane 1.5–2.0% and 
remifentanil 0.1–0.2 μg/kg/min. Patients were kept warm using 
a forced-air warming system (Bair-Hugger®, Augustine-Medi-
cal, Eden Prairie, MN, USA) to maintain a body temperature of 
36.0–37.0°C. Bispectral index (BIS) was measured continuously 
on a monitor (A-2000 BIS monitor, Aspect Medical Systems, 
Norwood, MA, USA) to maintain appropriate anesthetic depth 
throughout the operation. Thirty minutes before the end of sur-
gery, ondansetron 0.1 mg/kg was administered intravenously, 
and ketorolac 60 mg was given for postoperative pain manage-
ment. When the patients were able to obey commands, they 
were extubated. The total dose of remifentanil during anesthesia, 
and the pain score (0=no pain, 10=most extensive pain) upon 
arrival in the post anesthesia care unit were assessed.
The intensity of PONV was assessed during the first 2 hours 
after surgery and at 2–24 hours after surgery using a 10-cm vi-
sual analogue scale (0=no nausea, 10=most extensive nausea). 
At the same time, patients were monitored to determine 
whether an episode of vomiting occurred and whether anti-
emetics were administered. Episodes of retching were consid-
ered to be vomiting. During each time period, the maximal de-
gree of PONV experienced by the patient was recorded, and 
any episodes of nausea, retching or vomiting were defined as 
the presence of PONV. If a patient experienced no episodes of 
nausea or vomiting after the administration of ondansetron, he 
or she was allocated to the no-PONV group. When the patient 
vomited or requested a rescue antiemetic, metoclopramide 10 
mg was administered intravenously. Patients who reported a 
pain score >4 or requested rescue analgesics were treated with 
intramuscular injection of tramadol 50 mg. The primary end-
point of this study was the proportion of patients who did not ex-
perience any episodes of PONV after the administration of on-
dansetron for the prevention of PONV for each genotype group.
Genomic DNA was prepared from blood samples using a 
nucleic acid isolation device, QuickGene-mini80 (FUJIFILM, 
Tokyo, Japan). Genotyping for Y129S variants of the 5-HT3B re-
ceptor gene was screened through a single base primer exten-
sion assay using the ABI PRISM SNaPshot Multiplex kit (Applied 
Biosystem, Foster City, CA, USA) according to the manufactur-
er’s recommendations. Analysis was performed using Gene-
Mapper software (version 3.0; Applied Biosystems). Genotyp-
ing of the -100_-102AAG deletion variants of the 5-HT3B receptor 
gene was carried out using a DNA direct sequencing method. 
PCR was used to amplify one 5-HT3B fragment using UCSC In-
Silico PCR. The PCR products were purified using a Multi-
Screen384-PCR Filter Plate (Millipore, Billerica, MA, USA). The 
purified products were then sequenced using a BigDye Termi-
nator Cycle Sequencing Kit and an ABI 3730xl automated se-
quencer (Applied Biosystems). Mutation analyses were per-
formed using the Phred, Phrap, Consed, and Polyphred 5.04 
software packages (University of Washington, Seattle, WA, USA).
Considering that the expected frequency of the AAG deletion 
allele was 16.5% based on a previous study,14 we estimated that 
to achieve a power of 90% (α=0.05, β=0.1) when assuming a dif-
ference of 20% in the failure rate for ondansetron treatment 
among the genotypes, 240 patients would be required. There-
fore, we recruited 288 patients to compensate for excluded pa-
tients. The frequencies of the single nucleotide polymorphisms 
(SNPs) were assessed for deviation from Hardy-Weinberg equi-
librium using Fisher’s exact test. Frequency differences in geno-
type, demographic data, severity of PONV, and incidence of 
PONV were compared by the chi-square test, Fisher’s exact test, 
the Kruskal-Wallis test, or an ANOVA with Bonferroni correc-
tion as appropriate. Data were analyzed using SPSS version 15.0 
(SPSS Inc., Chicago, IL, USA). A value of  p<0.05 was considered 
significant.
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RESULTS
Of the 288 patients assessed to participate in this study, 43 were 
excluded from the study due to refusal to participate or sam-
pling error. Ultimately, a total of 245 patients were enrolled. 
There were no significant differences in patient characteristics 
and clinical data among genotypes (Table 1 and 2).
The frequencies of all genotypes were in Hardy-Weinberg 
equilibrium (p>0.05). Frequencies of the 5-HT3B AAG deletion 
genotypes were as follows: 77.6% for wild type, 19.6% for het-
eromutant, and 2.8% for homomutant. Among the 5-HT3B AAG 
deletion genotypes, the incidence of PONV was higher in pa-
tients with a homomutant genotype than other genotypes dur-
ing the first 2 hours after surgery (Codominant model, p=0.02) 
(Table 3). This difference was also statistically significant when 
analyzed between the patients with and without the Ins/ins 
(Dominant model, p=0.04) or the Del/del genotype (Recessive 
model, p=0.02), respectively. There were no significant differ-
ences in the incidence of PONV among genotypes at 2–24 
hours after surgery. In the Y129S variants of the 5-HT3B recep-
tor gene, there were no significant differences in the incidence 
of PONV among genotypes during the first 2 hours or at 2–24 
hours after surgery (Table 4).
The severity of nausea was significantly higher in patients 
with a homomutant genotype than other genotypes during the 
first 2 hours after surgery in the 5-HT3B AAG deletion geno-
types (p=0.02) (Table 5). There were no significant differences 
in the severity of nausea among genotypes in the Y129S vari-
ants of the 5-HT3B receptor gene (Table 6).
DISCUSSION
The present study revealed a significant association between 
the -100_-102AAG deletion polymorphism and the efficacy of 
ondansetron. The patients with a homomutant genotype of the 
-100_-102AAG deletion variant had a higher incidence of 
PONV than other genotypes during the first 2 hours after sur-




Number of patients 190 48 7
Gender (M/F) 80/110 20/28 3/4
Age (yr)   46 (21–65)   46 (23–65)   51 (45–57)
Weight (kg) 64.4 (10.3) 64.7 (11.2) 60.7 (10.9)
History of smoking 22 7 2
History of PONV 3 1 0
History of motion sickness 28 8 1
Duration of surgery (min) 72 (30) 70 (26) 74 (20)
Remifentanil doses in OR (µg) 505 (210) 504 (222) 656 (328)
Pain score in PACU 5 (3–6) 4 (3–6) 4 (3–4)
Number of patients who required rescue analgesics 93 30 3
Ins, insertion; Del, deletion; PONV, postoperative nausea and vomiting; OR, operation room; PACU, post-anesthesia care unit.
Values are presented as mean (range) for age, median (interquartile range) for pain score, mean (SD), or number of patients.




Number of patients 146 83 16
Sex (M/F) 64/82 33/50 6/10
Age (yr)   47 (23–65)   45 (21–65)   48 (31–61)
Weight (kg) 64.5 (10.3) 64.7 (11.4) 62.6 (6.8)
History of smoking 18 12 1
History of PONV 4 0 0
History of motion sickness 27 9 1
Duration of surgery (min) 73 (31) 70 (26) 69 (22)
Remifentanil doses in OR (µg) 513 (231) 505 (189) 501 (229)
Pain score in PACU 5 (3–6) 4 (3–6) 5 (4–6)
Number of patients who required rescue analgesics 71 47 8
PONV, postoperative nausea and vomiting; OR, operation room; PACU, post anesthesia care unit.
Values are presented as mean (range) for age, median (interquartile range) for pain score, mean (SD), or number of patients. 
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gery; however, the Y129S genotypes were not related to the 
clinical response to ondansetron.
The 5-HT3 receptor antagonists have been used effectively in 
order to prevent PONV.5,7 Unfortunately, all patients do not 
show a favorable outcome when the drug is administered.3 This 
therapeutic failure may be partially explained by other complex 
mechanisms of PONV, such as the effects of histamine, dopa-
mine, and opioids other than 5-HT3.1,15 Considering the in-
creased occurrence of PONV in several generations of the same 
family, considerable concordance of PONV in twins, and the 
established high risk of PONV in children with a family history 
of PONV, the individual variability of drug responses can also 
be associated with inherited differences in genes modifying the 
drug’s actions.10 This variability in drug action may be pharma-
cokinetic or pharmacodynamic.8 Genetic variations affecting 
the efficacy of 5-HT3 receptor antagonists have also been stud-
ied from a pharmacokinetic and pharmacodynamic perspec-
tive.10,13,16
The primary target in pharmacokinetic investigations in-
cludes the CYP450 2D6 isoform (CYP2D6) associated with 
metabolic pathways of 5-HT3 receptor antagonists. Polymor-
phic variations of the CYP2D6 system may induce ultra-rapid 
metabolism and subsequent therapeutic failure of 5-HT3 re-
ceptor antagonists.10
Table 5. Effects of 5-HT3B AAG Deletion Genotype on the Efficacy of 
Ondansetron for Nausea Severity
First 2 hrs 2–24 hrs
Genotypes 
Ins/ins 0 (0–3) 0 (0–0)
Ins/del 0 (0–4) 0 (0–0)
Del/del 4 (2–5) 0 (0–0)
p values
Overall 0.03 0.43
Non-Del/del vs. Del/del 0.02 0.33
Ins/ins vs. Non-Ins/ins 0.05 0.26
Ins, insertion; Del, deletion.
Values are median (interquartile range). 
Table 6. Effects of Y129S Variants of the 5-HT3B Receptor Gene on the 
Efficacy of Ondansetron for Nausea Severity 
First 2 hrs 2–24 hrs
Genotypes 
AA 0 (0–4) 0 (0–0)
AC 0 (0–3) 0 (0–0)
CC 0 (0–4) 0 (0–0)
p values
Overall 0.67 0.53
AA+AC vs. CC 0.37 0.35
AA vs. AC+CC 0.81 0.36
Values are median (interquartile range). 
Table 3. Effects of 5-HT3B AAG Deletion Genotype on the Efficacy of Ondansetron for Postoperative Nausea and Vomiting
First 2 hrs 2–24 hrs 
No PONV PONV No PONV PONV
Genotypes 
Ins/ins 119 (62.6) 71 (37.4) 167 (87.9) 23 (12.1)
Ins/del 25 (52.1) 23 (47.9) 44 (91.7) 4 (8.3)
Del/del 1 (14.3) 6 (85.7) 7 (100.0) 0 (0.0)
p values
Overall 0.02 0.49
Ins/ins vs. Non-Ins/ins 0.04 0.31
Non-Del/del vs. Del/del 0.02 1.00
Ins, insertion; Del, deletion; PONV, postoperative nausea and vomiting.
Values are number of patients (%). 
Table 4. Effects of Y129S Variants of the 5-HT3B Receptor Gene on the Efficacy of Ondansetron for Postoperative Nausea and Vomiting
First 2 hrs 2–24 hrs
No PONV PONV No PONV PONV
Genotypes 
AA 89 (61.0) 57 (39.0) 131 (89.7) 15 (10.3)
AC 48 (57.8) 35 (42.2) 73 (88.0) 10 (12.0)
CC 8 (50.0) 8 (50.0) 14 (87.5) 2 (12.5)
p values
Overall 0.67 0.90
AA vs. AC+CC 0.49 0.65
AA+AC vs. CC 0.44 0.69
PONV, postoperative nausea and vomiting.
Values are number of patients (%).
1419http://dx.doi.org/10.3349/ymj.2015.56.5.1415
Min-Soo Kim, et al.
Variations in genes encoding the target molecule of a drug as 
pharmacodynamic factors are associated with an alteration of 
drug activity.8 As the primary target of 5-HT3 receptor antago-
nists, the 5-HT3 receptor is a ligand-operated ion channel that 
includes five different receptor subunits (5-HT3A, B, C, D, and 
E) identified in humans.8,17 The 5-HT3A subunits are capable of 
forming a functional homomeric complex of the 5-HT3 recep-
tor, whereas the 5-HT3B subunit forms a heteromeric complex 
through an association with the 5-HT3A subunit.8,16 The prima-
ry differences between the homomeric 5-HT3A and hetero-
meric 5-HT3A/3B complexes are biologic characteristics, con-
ductance, and other slight differences in their pharmacological 
properties.8,17 The function and expression of the 5-HT3 recep-
tor can be affected through variation of the genes coding its 
subunits; in particular, polymorphisms of the 5-HT3B subunit 
gene can modify the pharmacological and functional proper-
ties of the 5-HT3 receptor.17,18 The Y129S and -100_-102AAG de-
letions investigated in this study are the typical genetic varia-
tions of the 5-HT3B subunit.9,10,16 Y129S is a substitution of an 
amino-acid located in the coding region of the 5-HT3B subunit 
gene. Sugai, et al.12 demonstrated that the Y129S polymorphism 
significantly affected the incidence of nausea induced by par-
oxetine; however, in a previous study on the efficacy of 5-HT3 
receptor antagonists in CINV, the Y129S polymorphism did not 
change the incidence of CINV.13 In this study, the Y129S poly-
morphism also did not change the response to ondansetron for 
PONV. Although this inconsistency may be explained by differ-
ences in factors such as paroxetine use, emetogenic chemo-
therapy administration, and general anesthesia, the reason for 
the inconsistent results is not clear.12 The -100_-102AAG dele-
tion is a 3-base pair deletion within the 5’untranslated region of 
the 5-HT3B subunit gene.10 Tremblay, et al.13 demonstrated that 
this deletion variant in the promoter region was significantly 
associated with a high incidence of CINV, whereas Rueffert, et 
al.9 did not confirm this specific result in patients with PONV. 
The present study showed that patients who were homomutant 
for the AAG deletion genotype had a higher incidence of PONV 
than other genotypes. The discrepancy between Rueffert’s and 
our results may have been caused by differences in patient 
characteristics and study design.9
Despite our favorable result, the functional impact of the 
-100_-102AAG deletion on the 5-HT3B receptor subunit is not 
yet obvious, and an in vitro study on the functional aspects of 
polymorphisms related to the 5-HT3B receptor subunit is still 
lacking.13 Furthermore, various issues related to the interactions 
existing between the subunits that make up the 5-HT3 receptor 
have not been fully explained, even though the 5-HT3B recep-
tor subunit is likely to play an important functional role, consid-
ering the current knowledge about the 5-HT3 receptor.18 How-
ever, a previous study using secondary structure prediction 
showed that this polymorphism can cause a structural modifi-
cation of mRNA when compared with the wild type.19 Meineke, 
et al.20 demonstrated that the -100_-102AAG deletion increased 
the promoter activity of the 5-HT3B receptor gene in vitro. In 
addition, this variant is a deletion of three nucleotides. There-
fore, it could have a much greater impact on the receptor func-
tion than other single nucleotide polyporphisms.13
We found that the response to ondansetron for PONV did not 
differ according to the 5-HT3B -100_-102AAG deletion geno-
types at 2–24 hours after surgery; however, in this study, 89% or 
more patients did not suffer from PONV between 2 and 24 
hours, which may explain the lack of association observed dur-
ing this time period.
There are a variety of risk factors that can affect the develop-
ment of PONV. It is well-documented that female gender, a pre-
vious history of PONV or motion sickness, the use of intrave-
nous opioids, and non-smoking status are the main predictors 
of PONV.15,21 In this study, we did not find any significant differ-
ences in these predictors based on genotype. In order to mini-
mize the influence of anesthetic and surgical factors on our re-
sults, we enrolled patients who underwent an identical surgical 
procedure and performed general anesthesia using the same 
anesthetic agent while maintaining BIS values at a constant lev-
el. Furthermore, our study confirmed that genotype distribu-
tion of the Y129S SNP and -100_-102AAG deletion of the 5-HT3B 
receptor gene was in accordance with Hardy-Weinberg equilib-
rium, suggesting that our finding involving this receptor gene is 
likely robust.
We concluded that the response to ondansetron for PONV 
was significantly influenced by the -100_-102AAG deletion 
polymorphisms of the 5-HT3B gene. Taking these results into 
account, the -100_-102AAG deletion variants may be a phar-
macogenetic predictor of responsiveness to ondansetron for 
PONV. Further research is needed to clarify the functional role 
of this polymorphism in the 5-HT3B subunit and the interac-
tion between the 5-HT3 receptor subunits.
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